January 17, 2018 / 6:27 AM / 8 months ago

BRIEF-Pharming Announces FDA Acceptance For Review Of Supplemental Biologics License Application

Jan 17 (Reuters) - PHARMING GROUP NV:

* PHARMING ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS

* ‍FDA INDICATED SBLA IS SUFFICIENTLY COMPLETE TO PERMIT SUBSTANTIVE REVIEW

* ‍FDA SET AN ACTION DATE OF SEPTEMBER 21, 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below